NCT01497652已完成4 期
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Montreal Cognitive Assessment
研究概览
简要总结
The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II & III at the end of week 14.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged 40 or older with idiopathic Parkinson's disease on stable dopaminergic therapy for at least 1 month. The UK Brain Bank Criteria will be used to establish the diagnosis of Parkinson's disease. Women must be post menopausal or agree to avoid pregnancy. Modified Hoehn & Yahr staging < 3 and MoCA score must be greater than 21 but less than
- •Geriatric Depression Scale (GDS) is a sensitive and specific screen for depression in the Parkinson's disease population. GDS scores of < 5 will be included in the study.
排除标准
- •Patients with secondary dementia, severe depression and atypical Parkinson's syndromes or Parkinson's plus will be excluded from the study. Patients on acetylcholine esterase or NMDA inhibitor medication will be excluded from the study. Patients with history of brain surgery for Parkinson's disease, stroke or significant head injury, active epilepsy will be excluded. Patients on Amantidine, neuroleptics, metoclopramide, alphamethyldopa within the last 6 months will be excluded. Individuals using meperidine, and tramadol will be excluded. Patients with congestive heart failure or myocardial infarction will also be excluded to avoid vascular dementia.
研究组 & 干预措施
Treatment Group
Active Comparator
Treatment group will receive Rasagiline (Azilect) 1mg daily
干预措施: Rasagiline (Drug)
Placebo Group
Placebo Comparator
will receive placebo daily
干预措施: Rasagiline/Placebo (Drug)
结局指标
主要结局
Montreal Cognitive Assessment
时间窗: 14 Weeks
Best value is 30 and Worst Value is 0. Scores for a series of subscales are not combined for a total overall score.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyProgressive Supranuclear PalsyNCT01187888Prof. Dr. Stefan Lorenzl44
已完成
4 期
Rasagiline and Apathy in Parkinson's DiseaseParkinson's DiseaseNCT00755027Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau40
已完成
2 期
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseParkinson's Disease With Cognitive ImpairmentsNCT01211587Newron Pharmaceuticals SPA103
已完成
2 期
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With SchizophreniaCognitive Deficits in SchizophreniaNCT01077700AbbVie (prior sponsor, Abbott)214
已完成
2 期
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With SchizophreniaCognitive Deficits in SchizophreniaNCT01095562AbbVie (prior sponsor, Abbott)207